NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 7044-7052

  Diallo, Jean Simon ^a   Aldejmah, Abdulhadi ^a,d   Mouhim, Abdelali Filali ^a   Péant, Benjamin ^a   Fahmy, Mona Alam ^a   Koumakpayi, Ismaël Hervé ^a   Sircar, Kanishka ^b   Bégin, Louis R ^c   Mes Masson, Anne Marie ^a,d   Saad, Fred ^a,d,e  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN NOXA; PUMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER MODEL; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONFIDENCE INTERVAL; DISEASE MARKER; GLEASON SCORE; HORMONE SENSITIVITY; HUMAN; HUMAN TISSUE; MALE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REGRESSION ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; TISSUE SECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; DISEASE PROGRESSION; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL;

EID: 37249080636     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1224     Document Type: Article

References (61)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA CancerJ Clin 1999;49:8-31, 1.
3. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993;72:3888-95.
4. Culine S, Droz JP. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? Ann Oncol 2000;11:1523-30.
5. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
6. Morris MJ, Scher HI. Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer 2000;89:1329-48.
7. Coughlin SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol 2002;12:182-96.
8. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002;9:601-10.
9. Ratan HL, Gescher A , Steward WP, Mellon JK. ErbB receptors: possible therapeutic targets in prostate cancer? BJU Int 2003;92:890-5.
10. Gavrielides MV, Frijhoff AF, Conti CJ, Kazanietz MG. Protein kinase C and prostate carcinogenesis: targeting the cell cycle and apoptotic mechanisms. Curr Drug Targets 2004;5:431-43.
11. Yang YM, Bost F, Charbono W, et al. C-Jun NH (2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 2003;9:391-401.
12. Edwards J, Krishna NS, Mukherjee R, Bartlett JM. The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. J Pathol 2004;204:153-8.
13. Chesire DR, Isaacs WB. β-Catenin signaling in prostate cancer: an early perspective. Endocr Relat Cancer 2003;10:537-60.
14. Libertini SJ, Tepper CG, Guadalupe M, et al. E2F1 expression in LNCaP prostate cancer cells deregulates androgen dependent growth, suppresses differentiation, and enhances apoptosis. Prostate 2006;66:70-81.
15. Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis 2003;8:29-37.
16. Tantivejkul K, Loberg RD, Mawocha SC, et al. PAR1-mediated NFκB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 2005;96:641-52.
17. Zellweger T, Ninck C, Bloch M, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005;113:619-28.
18. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-76.
19. Augustin H, Hammerer PG, Graefen M, et al. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy. J Cancer Res Clin Oncol 2003;129:662-8.
20. Pollack A, Cowen D, Troncoso P, et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 2003;97:1630-8.
21. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
22. Viktorsson K, Lewensohn R, Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res 2005;94:143-96.
23. Amirghofran Z, Monabati A, Gholijani N. Apoptosis in prostate cancer: bax correlation with stage. Int J Urol 2005;12:340-5.
24. Rubio J, Ramos D, Lopez-Guerrero JA, et al. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 2005;48:745-51.
25. Royuela M, De Miguel MP, Bethencourt FR, et al. IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors 2000;18:135-46.
26. Chia SJ, Tang WY, Elnatan J, et al. Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker. Br J Cancer 2000;83:761-8.
27. Kim H, Rafiuddin-Shah M, Tu HC, et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006;8:1348-58.
28. Cartron PF, Gallenne T, Bougras G, et al. The first a helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol Cell 2004;16:807-18.
29. Karst AM, Dai DL, Martinka M, Li G. PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 2005;24:1111-6.
30. Karst AM, Dai DL, Cheng JQ, Li G. Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival. Cancer Res 2006;66:9221-6.
31. Jansson A, Arbman G, Sun XF. mRNA and protein expression of PUMA in sporadic colorectal cancer. Oncol Rep 2004;12:1245-9.
32. Jansson AK, Emterling AM, Arbman G, Sun XF. Noxa in colorectal cancer: a study on DNA, mRNA and protein expression. Oncogene 2003;22:4675-8.
33. Therneau TAE. An introduction to recursive partitioning using the rpart routine. Technical Report. Rochester: Section of Biostatistics, Mayo Clinic; 1997.
34. Breiman LFJ, Olshen RA, Stone CJ. Classification and regression trees. California: CRC Press; 1984.
35. Fradet V, Lessard L, Begin LR, et al. Nuclear factor-κB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 2004;10:8460-4.
36. Koumakpayi IH, Diallo JS, Le Page C, et al. Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. BJU Int 2007;100:303-9.
37. Le Page C, Koumakpayi IH, Alam-Fahmy M, Mes-Masson AM, Saad F. Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer 2006;94:1906-12.
38. Lessard L, Mes-Masson AM, Lamarre L, et al. NF-κB nuclearl ocalization and its prognostic significance in prostate cancer. BJU Int 2003;91:417-20.
39. Koumakpayi IH, Diallo JS, Le Page C, et al. Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res 2006;12:2730-7.
40. Gannon PO, Alam Fahmy M, Begin LR, et al. Presence of prostate cancer metastasis correlates with lower lymph node reactivity. Prostate 2006;66:1710-20.
41. Edwards J, Traynor P, Munro AF, et al. The role of HER1-4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 2006;12:123-30.
42. Graf E, Schmoor C, Sauerbrei W, Schumacher M. Assessment and comparison of prognostic classification schemes for survival data. Stat Med 1999;18:2529-45.
43. Effron BTRJ. An introduction to the bootstrap. New York: Chapman and Hall; 1993.
44. Team RDC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation fro Statistical Computing; 2006.
45. Hershko T, Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 2004;279:8627-34.
46. Su X, Tsai CL. Tree-augmented Cox proportional hazards models. Biostatistics 2005;6:486-99.
47. De Rose A, Pallara A. Survival trees: an alternative non-parametric multivariate technique for life history analysis. Eur J Popul 1997;13:223-41.
48. LeBlanc M, Crowley J. Relative risk trees for censored survival data. Biometrics 1992;48:411-25.
49. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003;169:164-9.
50. Steuber T, Graefen M, Haese A, et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol 2006;175:939-44; discussion 44.
51. Garzotto M, Park Y, Mongoue-Tchokote S, et al. Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies. Cancer 2005;104:1911-7.
52. Garzotto M, Beer TM, Hudson RG, et al. Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol 2005;23:4322-9.
53. Rubin MA, Bismar TA, Andren O, et al. Decreased α-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005;14:1424-32.
54. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;19:453-73.
55. Radespiel-Troger M, Hohenberger W, Reingruber B. Improved prediction of recurrence after curative resection of colon carcinoma using tree-based risk stratification. Cancer 2004;100:958-67.
56. Stapleton AM, Zbell P, Kattan MW, et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 1998;82:168-75.
57. Zeng L, Rowland RG, Lele SM, Kyprianou N. Apoptosis incidence and protein expression of p53,TGF-β receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum Pathol 2004;35:290-7.
58. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 1998;110:443-9.
59. Bubendorf L, Tapia C, Gasser TC, et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998;29:949-54.
60. You H, Pellegrini M, Tsuchihara K, et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 2006;203:1657-63.
61. Obexer P, Geiger K, Ambros PF, Meister B, Ausserlechner MJ. FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ 2007;14:534-47.